inspiring canadians to live better.

healthing leaf

inspiring canadians to live better.

healthing leaf
get healthing in your inbox with the morning checkup and weekender newsletter!

wegovy approved for lowered risk of heart attack: what it means for people living with obesity and heart disease

wegovy is giving people living with obesity and those at risk of heart attack a new therapeutic option that will tackle both.

by angelica bottaro
published nov 27, 2024
read time 4 minute read
join the conversation
read time 4 minute read
join the conversation
while there are current therapies available for people living with obesity and heart disease, the introduction of a one-step drug for both can make living with both conditions much more manageable, both physically and mentally. getty images
wegovy, a semaglutide injection produced by novo nordisk, has made waves for its ability to foster weight reduction in people living with obesity. more recently, the drug has been heavily studied for other applications. one such use, non-fatal myocardial infarction or heart attack, is one of those applications. the drug, which was approved for treating obesity in november 2021 and became accessible to canadians in may 2024, was investigated for its benefits against heart attack in people living with overweight or obesity in the semaglutide effects on cardiovascular outcomes in people with overweight or obesity select trial.
the results of the trial revealed that wegovy reduced the risk of major adverse cardiovascular events (mace) in adults with cardiovascular disease and a bmi over 27 kg/m², earning health canada’s approval as a treatment to lower the risk of non-fatal myocardial infarction.
“heart attacks have a profound impact on many families across our country. wegovy is a clinically evaluated therapy that offers new hope for canadians living with cardiovascular disease and obesity,” said vince lamanna, president of novo nordisk canada inc., in a press release.

related stories

signs point to glp-1 drug innovation beyond wegovy and ozempic
with the explosive demand for breakthrough drugs like wegovy and ozempic for weight loss, pharmaceutical companies are racing to improve these medications and target additional conditions.
according to a national survey from dalhousie university’s agri-food analytics lab, between 900,000 and 1.4 million canadians are currently using a glp-1 drug to manage weight loss and diabetes.

study highlights wegovy's expanding benefits from obesity to heart disease
the obesity drug wegovy shows promise in treating heart disease as well as obesity, diabetes, and renal disease.
dr. subodh verma was also part of other studies looking into using semaglutide in the treatment of heart disease driven by obesity, and the results of those trials were just as promising.
story continues below
this new indication for an already well-established drug gives patients another tool for achieving and maintaining a healthy weight while improving heart health.

the first health canada-approved treatment for weight and non-fatal heart attack risk management

roughly one in three canadians live with obesity, according to the 2022 canadian community healthy survey. this condition brings on an increased risk for many other harmful conditions, including heart disease, another condition that affects millions of canadians.
along with obesity, there are many other risk factors for heart disease and stroke, including age, sex, other conditions such as diabetes, family history, and cultural and ethnic background. an estimated nine out of every 10 canadians have at least one of these risk factors.
heart attacks are the most common type of ischemic heart disease, and in canada, they are the leading cause of hospitalizations as well as the second-leading cause of death.
when it comes to obesity, according to the press release announcing the approval, “canadians living with obesity are more than twice as likely to have heart disease than those with a healthy weight.”
current approaches used to prevent heart attacks in people who are at a higher risk include:
powered by
obesity canada
story continues below
  • lifestyle changes, such as increasing exercise, eating healthier foods, managing weight, and avoiding smoking and alcohol
  • managing stress
  • using medications such as statins, aspirin, and dual antiplatelet therapy (a combination of aspirin and an antiplatelet drug)
the new approval marks the first of its kind in tackling both obesity and heart health in one medication. with obesity and heart disease closely linked, the use of wegovy in this multipurpose approach will help those living with both conditions improve the quality of their life.
“the introduction of semaglutide 2.4 mg as the only therapy proven to reduce non-fatal myocardial infarctions in patients living with overweight or obesity without diabetes is a remarkable breakthrough,” said dr. subodh verma, cardiac surgeon-scientist and professor at the university of toronto, in the release. “these data mark a new era in the treatment of obesity, shifting the focus from viewing it merely as a risk factor to recognizing it as a critical therapeutic target. this is a great advance and a pivotal moment for patients, representing a crucial step toward reducing the risk of first or recurrent heart attacks in this population.”
powered by
obesity matters
story continues below

what this means for obesity and heart disease patients

while there are current therapies available for people living with obesity and heart disease, the introduction of a one-step drug for both can make living with both conditions much more manageable, both physically and mentally.
on the physical side, taking wegovy can help those living with obesity reach and maintain a healthy weight. losing weight can reduce the risk of mace, but the drug’s added benefit can perpetuate that benefit even further.
on the mental side, weight loss in those living with obesity, as well as a reduced risk of heart attack, can improve a person’s level of anxiety and stress related to their conditions.
“people deserve evidence-based care to proactively manage this disease, including medical nutrition therapy, psychological interventions, physical activity, pharmacotherapy and surgery,” said dr. sanjeev sockalingam, scientific director of obesity canada, in the release.
overall, wegovy, with its proven effects on both weight management and mace, paints a picture of a future where people can reach and maintain a healthy weight while also improving their heart’s ability to function long term.
story continues below
the breakthrough aims to put better treatments into the hands of canadians – treatments that have been clinically proven as effective, offering next generation therapies that can continue to better the lives of those living with both heart attack risk factors and obesity or overweight.
angelica bottaro
angelica bottaro

angelica bottaro is the lead editor at healthing.ca, and has been content writing for over a decade, specializing in all things health. her goal as a health journalist is to bring awareness and information to people that they can use as an additional tool toward their own optimal health.

read more about the author

comments

postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. comments may take up to an hour for moderation before appearing on the site. we ask you to keep your comments relevant and respectful. we have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. visit our community guidelines for more information and details on how to adjust your email settings.

you may also like
obesity matters has developed a series of 12 wellness workshops starting this fall to bring wellness resources and experts free of charge to all people through informative and actionable virtual gatherings.
obesity matters wellness workshop: embracing wellness beyond the scale
the obesity matters leadership team, pictured, has worked tirelessly to develop resources to bring unprecedented support to people living with obesity in quebec through the organization's new french division, parlons obésité.
obesity matters launches french division to support and advocate for people in quebec  
a group of cheerful small school kids in canteen, eating lunch and talking.
understanding the childhood obesity epidemic: environment, genetics and education
neda nasseri, product director of benefits at desjardins insurance and advisory board member with obesity matters; rachel atkins, board vice-chair, director of strategy, and patient advocate with obesity matters; and dr. david attalla, internal medicine and obesity medicine physician. (left to right)
the toll of obesity: long-term impact, access to care and insurance support
two packages of 5 dosing pens each of a fictitious semiglutin drug used for weight loss (antidiabetic medication or anti-obesity medication) on a blue transparent background. fictitious package design
signs point to glp-1 drug innovation beyond wegovy and ozempic
you may also like
obesity matters has developed a series of 12 wellness workshops starting this fall to bring wellness resources and experts free of charge to all people through informative and actionable virtual gatherings.
obesity matters wellness workshop: embracing wellness beyond the scale
the obesity matters leadership team, pictured, has worked tirelessly to develop resources to bring unprecedented support to people living with obesity in quebec through the organization's new french division, parlons obésité.
obesity matters launches french division to support and advocate for people in quebec  
a group of cheerful small school kids in canteen, eating lunch and talking.
understanding the childhood obesity epidemic: environment, genetics and education
neda nasseri, product director of benefits at desjardins insurance and advisory board member with obesity matters; rachel atkins, board vice-chair, director of strategy, and patient advocate with obesity matters; and dr. david attalla, internal medicine and obesity medicine physician. (left to right)
the toll of obesity: long-term impact, access to care and insurance support
you may also like
obesity matters has developed a series of 12 wellness workshops starting this fall to bring wellness resources and experts free of charge to all people through informative and actionable virtual gatherings.
obesity matters wellness workshop: embracing wellness beyond the scale
the obesity matters leadership team, pictured, has worked tirelessly to develop resources to bring unprecedented support to people living with obesity in quebec through the organization's new french division, parlons obésité.
obesity matters launches french division to support and advocate for people in quebec